Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Haematological Malignancies
NCT01658241Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in Hodgkin lymphoma (HL), multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), cutaneous B-cell lymphoma (PCBCL), sponsored by Peter MacCallum Cancer Centre. Started Jul 2012; status: completed.
02
Drugs
panobinostat
03
Conditions
Hodgkin lymphoma (HL)multiple myeloma (MM)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)cutaneous B-cell lymphoma (PCBCL)
Beyond the preview
Go deeper on NCT01658241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658241.